“This funding will allow Flagship to further expand our market leadership in creating biomarker data and strategies that accelerate drug and diagnostic development for better patient care,” says Trevor D. Johnson, Flagship CEO.
WESTMINSTER, Colo. (PRWEB) July 10, 2018
Flagship Biosciences has closed a series A round of funding to advance the growth of its computational tissue image analysis technology platform and biomarker-driven drug development and diagnostic services.
Since 2009, Flagship’s integrated team of scientists, pathologists, tissue and data analysts, and software engineers has worked with some of the world’s largest and most respected pharmaceutical and biotech companies to develop solutions that treat, manage, and cure the world’s most challenging medical conditions.
Flagship will use this investment to advance its industry-leading tissue image analysis software and operational workflow, as well as increase its commercial footprint to better facilitate drug development partnerships and precision medicine.
“This funding will allow Flagship to further invest in our technology platform and commercial operations, expanding our market leadership in creating rich, contextual biomarker data and strategies that help accelerate drug and diagnostic development for better patient care,” says Trevor D. Johnson, Flagship Biosciences CEO.
Flagship has completed more than 500 projects across the development spectrum, advancing the precision medicine objectives of 6 of the 10 largest pharmaceutical companies. Flagship holds 12 U.S. patents supporting its proprietary digital tissue analysis technology.
About Flagship Biosciences
Flagship Biosciences helps drug developers confidently define their path to success. Our cTA platform and decision support process for tissue biomarkers applies computational tissue analysis to make timely decisions. For more information on how Flagship accelerates drug development, please visit flagshipbio.com and follow Flagship on Twitter @FlagshipBio.